Merck & Co Names New CEO

BMI View: The share price of Merck & Co will continue trading sideways until a positive catalyst is introduced. This stimulus is likely to be an enhanced strategy for the high-growth emerging markets or the launch of a future blockbuster medicine. Significant downside risks to this outlook are another major product recall or a negative outcome from the Remicade (infliximab)/Simponi (golimumab) arbitration.

To read the full article, please choose one of the following options: